Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Diroximel fumarate	TA794: Diroximel fumarate for treating relapsing–remitting multiple sclerosis
Docetaxel injection	TA214 - Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer TA109 - Docetaxel for the adjuvant treatment of early node-positive breast cancer TA101 - Docetaxel for the treatment of hormone-refractory metastatic prostate cancer	Negative TA
Donepezil orodispersible tablets	TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	Dementia drugs ESCA
Donepezil tablets	TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	Dementia drugs ESCA
Doxorubicin injection	TA91 - Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer
Doxorubicin liposomal infusion	TA91 - Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer	National CDF list
Dronedarone tablets	TA197 - Dronedarone for the treatment of non-permanent atrial fibrillation
Dupilumab	TA534 - Dupilumab for treating moderate to severe atopic dermatitis TA751 - Dupilumab for treating severe asthma with type 2 inflammation
Durvalumab	TA578 - Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
Edoxaban	TA355 - Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation TA354 - Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism	First choice following a diagnosis of AF - use in line with NICE Anticoagulant Initiation Flowchart for Anticoagulation in Atrial Fibrillation

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.